Format

Send to

Choose Destination
J Am Coll Cardiol. 2014 Jan 21;63(2):158-66. doi: 10.1016/j.jacc.2013.07.087. Epub 2013 Sep 24.

Head-to-head comparison of 2 myocardial fibrosis biomarkers for long-term heart failure risk stratification: ST2 versus galectin-3.

Author information

1
Heart Failure Unit, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain; Department of Medicine, Autonomous University of Barcelona, Barcelona, Spain. Electronic address: grupicrec@gmail.com.
2
Heart Failure Unit, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain; Department of Medicine, Autonomous University of Barcelona, Barcelona, Spain.
3
Hospital del Mar Medical Research Institute, Barcelona, Spain; CIBER Epidemiology and Public Health, Barcelona, Spain.
4
Biochemistry Service, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain.

Abstract

OBJECTIVES:

ST2 and galectin-3 (Gal-3) were compared head-to-head for long-term risk stratification in an ambulatory heart failure (HF) population on top of other risk factors including N-terminal pro-B-type natriuretic peptide.

BACKGROUND:

ST2 and Gal-3 are promising biomarkers of myocardial fibrosis and remodeling in HF.

METHODS:

This cohort study included 876 patients (median age: 70 years, median left ventricular ejection fraction: 34%). The 2 biomarkers were evaluated relative to conventional assessment (11 risk factors) plus N-terminal pro-B-type natriuretic peptide in terms of discrimination, calibration, and reclassification analysis. Endpoints were 5-year all-cause and cardiovascular mortality, and the combined all-cause death/HF hospitalization.

RESULTS:

During a median follow-up of 4.2 years (5.9 for alive patients), 392 patients died. In bivariate analysis, Gal-3 and ST2 were independent variables for all endpoints. In multivariate analysis, only ST2 remained independently associated with cardiovascular mortality (hazard ratio: 1.27, 95% confidence interval [CI]: 1.05 to 1.53, p = 0.014). Incorporation of ST2 into a full-adjusted model for all-cause mortality (including clinical variables and N-terminal pro-B-type natriuretic peptide) improved discrimination (C-statistic: 0.77, p = 0.004) and calibration, and reclassified significantly better (integrated discrimination improvement: 1.5, 95% CI: 0.5 to 2.5, p = 0.003; net reclassification index: 9.4, 95% CI: 4.8 to 14.1, p < 0.001). Incorporation of Gal-3 showed no significant increase in discrimination or reclassification and worse calibration metrics. On direct model comparison, ST2 was superior to Gal-3.

CONCLUSIONS:

Head-to-head comparison of fibrosis biomarkers ST2 and Gal-3 in chronic HF revealed superiority of ST2 over Gal-3 in risk stratification. The incremental predictive contribution of Gal-3 to existing clinical risk factors was trivial.

KEYWORDS:

AIC; Akaike information criterion; BIC; Bayesian information criterion; CI; Gal-3; HF; HR; IDI; IQR; LVEF; N-terminal pro–B-type natriuretic peptide; NRI; NT-proBNP; ST2; biomarkers; confidence interval; galectin-3; hazard ratio; heart failure; high-sensitivity soluble ST2; integrated discrimination improvement; interquartile range; left ventricular ejection fraction; myocardial fibrosis; net reclassification improvement; remodeling; survival

PMID:
24076531
DOI:
10.1016/j.jacc.2013.07.087
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center